We are pleased to share with you that WuXi Healthcare Ventures (WXHV) has joined a $61M Series D financing round of Twist Bioscience and a $40M financing around for Syros Pharmaceuticals.

Founded in 2013 in San Francisco, Twist has developed an automated semiconductor-based synthetic gene manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, including genes, oligonucleotide pools, and variant libraries.  By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, this platform enables cost-effective, rapid, high-quality, and high-throughput synthetic gene production and overcomes the current inefficiencies  of synthetic DNA production.   The Twist platform has the potential to accelerate the application of DNA synthesis in drug development, biofuel and chemical production, agriculture production, biodetection, and data storage.  WXHV initially invested in Twist’s Series B financing in May 2014.  We are excited about the potential of Twist Bioscience’s automated platform to significantly lower the cost of DNA synthesis and thereby greatly expand the potential of genetic research.

Syros Pharmaceuticals, based in Cambridge, is focused on discovering and developing novel gene control therapies for cancer and other diseases.  Syros has built a proprietary platform based on its founders’ seminal discovery of super-enhancers, a new class of gene control elements that provides the company with a unique lens to identify crucial genes that become dysregulated in diseased cells.  By mapping gene control pathways directly in human disease tissue, Syros is pioneering a unique approach to identifying and modulating the gene switches important in diseases and identifying specific patient populations most likely to respond to these gene switches.  We are very pleased to support Syros’s development of new medicines based on the cutting-edge science of gene control.


Related Articles:

WuXi Healthcare Ventures II Closes with Oversubscription